Registering transparency: the making of the international clinical trial registry platform by the world health organization (2004-2006).
Clinical trial
Governance
Pharmaceutical Research
World Health Organization
Journal
Globalization and health
ISSN: 1744-8603
Titre abrégé: Global Health
Pays: England
ID NLM: 101245734
Informations de publication
Date de publication:
18 09 2023
18 09 2023
Historique:
received:
13
03
2023
accepted:
01
09
2023
medline:
20
9
2023
pubmed:
19
9
2023
entrez:
18
9
2023
Statut:
epublish
Résumé
This paper examines the events and conditions that led to the creation of the International Clinical Trials Registry Platform (ICTRP) in 2006 by the World Health Organization (WHO), and how the WHO addressed the issue of transparency in global pharmaceutical research. Using historical textual analysis, I trace the scientific debates that advocated for the establishment of official clinical trial registries in medical journals, and the sequence of actions following the GSK Paxil scandal in 2004, identifying the major ethical and scientific arguments that led to the involvement of the WHO as a key actor in trial registration in the context of the Big Pharma business model. Through the questions "Why register?" and "Why registries?" as a roadmap, I examine the issues of publication bias and selective reporting by the industry, scrutinizing two ways in which the practice of publication bias damaged transparency in industry-sponsored research. The first involved ethical concerns regarding human subject exploitation and concealing of negative results. The second addresses the deterioration of the certainty of evidence due to incomplete access to trials results. By reviewing the series of events that occurred between 2004 and 2006 -between the Paxil scandal and the launch of the ICTRP-, I analyze the actions taken by the different actors involved: (1) the International Committee of Medical Journal Editors (ICMJE) and the creation of the Ottawa Group; (2) the WHO, beginning with the Ministerial Summit on Health Research held in November of 2004, and (3) the responses of the pharmaceutical industry and specifically GSK to the call for transparency and trial registration. The history of trial registration through the ICTRP as a dataveillance apparatus shows the difficulty of regulating a health enterprise turned into a global business. Moreover, it shows the challenges of globalization and how easier and faster it is to globalize business compared to good practices, raising the question of why it has been so hard to undo these trends. Indeed, the history of the movement for trial registration is not a history of regulation success, or at least not yet.
Sections du résumé
BACKGROUND
This paper examines the events and conditions that led to the creation of the International Clinical Trials Registry Platform (ICTRP) in 2006 by the World Health Organization (WHO), and how the WHO addressed the issue of transparency in global pharmaceutical research. Using historical textual analysis, I trace the scientific debates that advocated for the establishment of official clinical trial registries in medical journals, and the sequence of actions following the GSK Paxil scandal in 2004, identifying the major ethical and scientific arguments that led to the involvement of the WHO as a key actor in trial registration in the context of the Big Pharma business model.
RESULTS
Through the questions "Why register?" and "Why registries?" as a roadmap, I examine the issues of publication bias and selective reporting by the industry, scrutinizing two ways in which the practice of publication bias damaged transparency in industry-sponsored research. The first involved ethical concerns regarding human subject exploitation and concealing of negative results. The second addresses the deterioration of the certainty of evidence due to incomplete access to trials results. By reviewing the series of events that occurred between 2004 and 2006 -between the Paxil scandal and the launch of the ICTRP-, I analyze the actions taken by the different actors involved: (1) the International Committee of Medical Journal Editors (ICMJE) and the creation of the Ottawa Group; (2) the WHO, beginning with the Ministerial Summit on Health Research held in November of 2004, and (3) the responses of the pharmaceutical industry and specifically GSK to the call for transparency and trial registration.
CONCLUSIONS
The history of trial registration through the ICTRP as a dataveillance apparatus shows the difficulty of regulating a health enterprise turned into a global business. Moreover, it shows the challenges of globalization and how easier and faster it is to globalize business compared to good practices, raising the question of why it has been so hard to undo these trends. Indeed, the history of the movement for trial registration is not a history of regulation success, or at least not yet.
Identifiants
pubmed: 37723473
doi: 10.1186/s12992-023-00970-5
pii: 10.1186/s12992-023-00970-5
pmc: PMC10506341
doi:
Substances chimiques
Paroxetine
41VRH5220H
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
71Informations de copyright
© 2023. BioMed Central Ltd., part of Springer Nature.
Références
New York Sues GlaxoSmithKline. The New York Times. (2004) https://www.nytimes.com/2004/06/02/business/new-york-sues-glaxosmithkline.html . Accessed Sept 13, 2022.
Rennie D. Trial registration: a great idea switches from ignored to irresistible. JAMA. 2004;292(11):1359–62.
doi: 10.1001/jama.292.11.1359
Keller MB, Ryan ND, Strober M, Klein RG, Kutcher SP, Birmaher B, Hagino OR, Koplewicz H, Carlson GA, Clarke GN, Emslie GJ. Efficacy of paroxetine in the treatment of adolescent major depression: a randomized, controlled trial. J Am Acad Child Adolesc Psychiatry. 2001;40(7):762–72.
doi: 10.1097/00004583-200107000-00010
Kondro W. Drug company experts advised staff to withhold data about SSRI use in children. CMAJ. 2004;170(5):783.
doi: 10.1503/cmaj.1040213
Glaxo faces criminal action in Britain over. “suicide” pills. Times of London; (2004). https://rense.com/general53/pax.htm . Accessed Sept 13, 2022.
Lancet. Is GSK guilty of fraud? The Lancet. 2004;363(9425):1919.
doi: 10.1016/S0140-6736(04)16435-0
Rettig RA. The Industrialization of Clinical Research: clinical research has become an industry of its own, one that warrants careful scrutiny to protect human research subjects. Health Aff. 2000;19(2):129–46.
doi: 10.1377/hlthaff.19.2.129
Malerba F, Orsenigo L. The evolution of the pharmaceutical industry. Bus Hist. 2015;57(5):664–87.
doi: 10.1080/00076791.2014.975119
H.R.7724–93rd Congress. (1973–1974): An Act to amend the Public Health Service Act to establish a program of National Research Service Awards to assure the continued excellence of biomedical and behavioral research and to provide for the protection of human subjects involved in biomedical and behavioral research and for other purposes. (1974). http://www.congress.gov/ . Accessed Sept 13, 2022.
Petryna A. When experiments travel. Princeton University Press; 2009 Apr. 27.
Gilbert J, Henske P, Singh A. Rebuilding big pharma’s business model. IN VIVO-NEW YORK THEN NORWALK-. 2003;21(10):73–80.
Angell M. The truth about the drug companies: how they deceive us and what to do about it. Random House Trade Paperbacks; 2005 Aug. p. 9.
Dickersin K, Min YI. Publication bias: the problem that won’t go away. Ann N Y Acad Sci. 1993;703:135–48.
doi: 10.1111/j.1749-6632.1993.tb26343.x
Dickersin K, Davis BR, Dixon DO, George SL, Hawkins BS, Lachin J, Peduzzig P, Pocock S. The Society for clinical trials supports United States legislation mandating trials registration. Clin Trails. 2004;1(5):417–20.
doi: 10.1191/1740774504cn039oa
Dickersin K, Rennie D. Registering clinical trials. JAMA. 2003;290(4):516–23.
doi: 10.1001/jama.290.4.516
Chalmers TC. Randomize the first patient! N Engl J Med. 1977;296(2):107.
doi: 10.1056/NEJM197701132960214
Simes RJ. Publication bias: the case for an international registry of clinical trials. J Clin Oncol. 1986;4:1529–41.
doi: 10.1200/JCO.1986.4.10.1529
The Lancet. Making clinical trialists register. Lancet. 1991;338:244–5.
doi: 10.1016/0140-6736(91)90371-U
Chalmers I. Underreporting research is scientific misconduct. JAMA. 1990;263(10):1405–08.
doi: 10.1001/jama.1990.03440100121018
Fisher J. Medical Research for Hire: the Political Economy of Pharmaceutical clinical trials. Ithaca, NY: Rutgers University Press; 2008.
Glickman SW, McHutchison JG, Peterson ED, Cairns CB, Harrington RA, Califf RM, Schulman KA. Ethical and scientific implications of the globalization of clinical research. N Engl J Med. 2009;360(8):816–23.
doi: 10.1056/NEJMsb0803929
National Bioethics Advisory Commission. Ethical and policy issues in international research: clinical trials in developing countries. Bethesda, Maryland. National Bioethics Advisory Commission; 2001.
Dickersin K, Chalmers I. Recognizing, investigating and dealing with incomplete and biased reporting of clinical research: from Francis Bacon to the WHO. J R Soc Med. 2011;104(12):532–8.
doi: 10.1258/jrsm.2011.11k042
Horton R, Smith R. Time to register randomised trials: the case is now unanswerable. BMJ. 1999;319(7214):865–6.
doi: 10.1136/bmj.319.7214.865
Evans T, Gülmezoglu M, Pang T. Registering clinical trials: an essential role for WHO. Lancet (London England). 2004;363(9419):1413–4.
doi: 10.1016/S0140-6736(04)16136-9
Law J. Big pharma: exposing the global healthcare agenda. New York: Carroll & Graf; 2006.
World Health Organization. WHO leads drive for international coordination of clinical research. World Health Organization. (2004). https://www.who.int/mediacentre/news/releases/2004/pr23/en/index.html . Accessed April 8, 2019.
De Angelis C, Drazen JM, Frizelle FA, Haug C, Hoey J, Horton R, et al. Clinical trial registration: a statement from the International Committee of Medical Journal editors. Ann Intern Med. 2004;141(6):477–8.
doi: 10.7326/0003-4819-141-6-200409210-00109
De Angelis C, Drazen JM, Frizelle FA, Haug C, Hoey J, Horton R et al. Update on Trials Registration. International Committee of Medical Journal Editors. (2004). http://www.icmje.org/news-and-editorials/trial_reg_oct2004.html . Accessed Sept 9, 2022.
Krleža-Jerić K. Clinical trial registration: the differing views of industry, the WHO, and the Ottawa Group. PLoS Med. 2005;2(11):e378.
doi: 10.1371/journal.pmed.0020378
Krleža-Jerić K, Chan AW, Dickersin K, Sim I, Grimshaw J, Gluud C. Principles for international registration of protocol information and results from human trials of health-related interventions: Ottawa statement (part 1). BMJ. 2005;330(7497):956–8.
doi: 10.1136/bmj.330.7497.956
World Health Organization. The Mexico statement on health research, World Health Organization. (2004). https://apps.who.int/gb/archive/pdf_files/EB115/B115_30-en.pdf . Accessed Sept 9, 2022.
Ghersi D, Pang T. From Mexico to Mali: four years in the history of clinical trial registration. J Evidence-Based Med. 2009;2(1):1–7.
doi: 10.1111/j.1756-5391.2009.01014.x
World Health Organization. WHA58.34 Ministerial Summit on Health Research. World Health Organization., (2005). https://apps.who.int/gb/ebwha/pdf_files/WHA58/WHA58_34-en.pdf Accessed Sept 9, 2022.
World Health Organization. WHO Drug Information. World Health Organization. (2005). https://apps.who.int/iris/bitstream/handle/10665/73385/19_2_2005.pdf?sequence=1 &isAllowed=y Accessed Sept 9, 2022.
World Health Organization. WHO clinical trials initiative to protect the public. Bulletin of the World Health Organization. Volume 84: 1. (2006). https://apps.who.int/iris/handle/10665/269553 . Accessed Sept 9, 2022.
World Health Organization. International standards for clinical trial registries. Version 3.0. (2018). https://apps.who.int/iris/bitstream/handle/10665/274994/9789241514743-eng.pdf . Accessed Sept 9, 2022.
Laine C et al. Update on trials registration: clinical trial registration: looking back and moving ahead. (2007). http://www.icmje.org/news-and-editorials/clincial_trial_reg_jun2007.html . Accessed April 10, 2019.
Jasso-Aguilar R. Multinational corporations, the State, and Contemporary Medicine. Health Sociol Rev. 2011;20:245–57.
doi: 10.5172/hesr.2011.20.3.245
Gibbs TG, Wager E. Realities of trial registration: the Glaxo Wellcome experience. Int J Pharm Med. 2000;14(4):203–5.
doi: 10.2165/00124363-200008000-00007
Kmietowicz Z. GSK backs campaign for disclosure of trial data. BMJ. 2013;346:f819.
doi: 10.1136/bmj.f819
The New York Times. Glaxo Agrees to Post Results Of Drug Trials on Web Site. (2004). https://www.nytimes.com/2004/08/27/business/glaxo-agrees-to-post-results-of-drug-trials-on-web-site.html . Accessed April 10, 2019.
GlaxoSmithKline. Public Disclosure of Clinical Research. (2018). https://www.gsk.com/media/2946/disclosure-of-clinical-trial-information-policy.pdf . Accessed Sept 7, 2022.
Wager E, Field EA, Grossman L. Good publication practice for pharmaceutical companies. Curr Med Res Opin. 2003;19(3):149–54.
doi: 10.1185/030079903125001767
International Federation of Pharmaceutical Manufacturers and Associations. Joint position on the disclosure of clinical trial information via clinical trial registries and databases. (2009). https://www.efpia.eu/media/25015/joint-position-on-the-disclosure-of-clinical-trial-information-via-clinical-trial-registries-and-databases-november-2009.pdf . Accessed March 6, 2023.
GlaxoSmithKline. Comments on Delayed Disclosure. (2006). https://www.who.int/ictrp/3008_GSK_25Jan06 .pdf Accessed March 3, 2019.
Goldhammer A, PhRMA Second Round Comments on International Clinical Trials Registry Platform (ICTRP) Disclosure Timing. (2006). https://www.who.int/ictrp/002-PhRMA_29March06.pdf . Accessed March 3, 2023.
Sim I, Chan AW, Gülmezoglu AM, Evans T, Pang T. Clinical trial registration: transparency is the watchword. The Lancet. 2006;367(9523):1631–3.
doi: 10.1016/S0140-6736(06)68708-4
Galič M, Timan T, Koops BJ, Bentham. Deleuze and beyond: an overview of surveillance theories from the panopticon to participation. Philos Technol. 2017;30:9–37.
doi: 10.1007/s13347-016-0219-1
Pansieri C, Pandolfini C, Bonati M. The evolution in registration of clinical trials: a chronicle of the historical calls and current initiatives promoting transparency. Eur J Clin Pharmacol. 2015;71(10):1159–64.
doi: 10.1007/s00228-015-1897-9
Birn AE, Pillay Y, Holtz TH. Textbook of global health. Oxford University Press; 2017 Jan. p. 24.
Weisz G, Nannestad B. The World Health Organization and the global standardization of medical training, a history. Globalization and Health. 2021;17(1):1–3.
doi: 10.1186/s12992-021-00733-0